Viatris Investor Event Summary Company Overview - **Company**: Viatris (NasdaqGS: VTRS) - **Date**: March 19, 2026 - **Key Leadership**: CEO Scott Smith, CFO Doretta Mistras, Chief R&D Officer Philippe Martin, Chief Commercial Officer Corinne Le Goff, Chief Strategy Officer Hemanth J. Varghese Core Business Segments - Viatris operates three main business segments: - **Global Generics**: A strong generics powerhouse - **Established Brands**: Includes iconic brands like Lipitor, Norvasc, Celebrex, Xanax, and Viagra - **Innovative Medicines**: A growing segment focusing on new drug development [6][5][4] Financial Performance and Projections - **2026 Revenue**: Expected to generate approximately $14.7 billion - **Adjusted EBITDA**: Projected at $4.3 billion - **EPS**: Anticipated at $2.40 per share - **Free Cash Flow**: Expected to be around $2.2 billion - **Long-term Targets (by 2030)**: - Total revenue growth: 5%-6% - Adjusted EBITDA growth: 7%-8% - Adjusted EPS growth: 9%-10% - Annual free cash flow: More than $3 billion [6][10][9] Strategic Initiatives - Focus on: - Driving base business growth - Fueling innovative portfolio development - Modernizing for sustainable growth - Plans to generate at least $11 billion in cash by 2030, balancing shareholder returns and business development [7][8][9] R&D and Pipeline Development - R&D focuses on three areas: - **Generic Medicines**: Core and complex generics - **Value-Added Medicines**: Established brands and 505(b)(2) applications - **Innovative Portfolio**: Emerging assets like Selatogrel and Cenerimod [15][16][22] Key Pipeline Assets - **Selatogrel**: A P2Y12 inhibitor for self-administered emergency treatment of recurrent myocardial infarction (MI). Expected to initiate a global registration study (SOS-MI) [26][27][30]. - **Cenerimod**: An oral S1P1 receptor modulator for systemic lupus erythematosus (SLE) and lupus nephritis. A pivotal program (OPUS) is underway with results anticipated in the first half of 2027 [31][32][36]. Commercial Strategy - Viatris has a robust commercial platform with a sales force of approximately 8,500 people, targeting growth across 165 countries [50][51]. - **Growth Drivers**: - **Europe**: Continued growth from promoted brands and generics leadership - **North America**: Leadership in complex generics and expansion of promoted brands - **Emerging Markets**: Focus on established brands leveraging physician trust [52][53][54] Upcoming Product Launches - **Fast-Acting Meloxicam**: A non-opioid option for acute pain, with peak net sales potential of up to $500 million [60][61]. - **Low-Dose Estrogen Contraceptive Patch**: Expected peak net sales of $180 million or higher, targeting young women [62][63]. - **Cenerimod and Selatogrel**: Anticipated global launches with blockbuster potential, with Cenerimod projected to exceed $1 billion in peak sales [65][68]. Conclusion - Viatris is positioned for durable growth through a diversified portfolio of generics, established brands, and innovative medicines. The company is focused on executing its strategic initiatives and leveraging its strong R&D capabilities to drive future success [69][70].

Summary of Viatris Conference Call Company Overview - **Company**: Viatris - **Business Segments**: - Global generics footprint (originating from Mylan) - Established products (notable brands include Lipitor, Norvasc, Xanax, Viagra, Celebrex from Upjohn acquisition) - Growing innovative segment [2][3] Core Points and Arguments - **Strategic Review**: Viatris is undergoing an enterprise-wide strategic review to assess its structure and cost efficiency, aiming for sustainable revenue and earnings growth beyond 2026 [4][20] - **Financial Performance**: - The company has returned over $1 billion to shareholders through dividends and share repurchases this year [3] - Anticipates approximately $500 million in new revenues annually from the base business, with a net growth of around $200 million after accounting for losses and price declines [8] - Internal expectations for revenue growth are higher than market estimates, with a goal to achieve continuous earnings growth over the next three to five years [7][26] - **Operating Leverage**: The company aims to improve operating leverage, targeting a growth profile shift from 1% to 3-5% [9][10] Pipeline and Product Development - **Innovative Assets**: Viatris is focusing on developing innovative products, including fast-acting meloxicam, which shows a faster onset of action compared to competitors [38][39] - **CNS Assets in Japan**: The acquisition of Aculys added CNS assets to Viatris' portfolio, with a strategic focus on growing revenues in the challenging Japanese market [32][34] - **Upcoming Launches**: The company is preparing for the launch of several products, including meloxicam and antiplatelet drugs, with significant market potential [46][63] Market Dynamics and Challenges - **External Challenges**: The company has faced external challenges such as tariffs, policy changes, and FDA regulations, which have impacted operations [2][3] - **Cost Structure Review**: Viatris is reviewing its cost structure post-merger and divestitures, aiming for significant cost savings while ensuring that these savings are sustainable [20][21] Investment and Capital Allocation - **Capital Deployment**: Viatris generates approximately $2 billion in free cash flow annually, with plans to allocate capital evenly between shareholder returns and business development [28][29] - **Focus on High-Margin Assets**: The company is looking to acquire high-margin, revenue-generating assets, particularly in the U.S. and Japan [35] Other Important Insights - **Market Positioning**: Viatris is positioning its innovative products as differentiated solutions in the market, with a focus on addressing unmet medical needs [39][63] - **Long-Term Vision**: The management emphasizes a long-term vision for growth, with a commitment to maintaining a strong base business while investing in innovation [6][26] This summary encapsulates the key points discussed during the Viatris conference call, highlighting the company's strategic direction, financial performance, product pipeline, and market challenges.

Summary of Sino Biopharmaceutical (1177.HK) Conference Call Company Overview - **Company**: Sino Biopharmaceutical - **Ticker**: 1177.HK - **Industry**: Pharmaceuticals, Biotech, and Medtech Key Points Product Sales Growth - Management reported an encouraging trend in product sales growth in 3Q, showing acceleration compared to 1H25, primarily driven by new products such as gasorasib (KRAS G12C), factor Ⅶa, and meloxicam [2][3] - Earnings growth is expected to outpace topline growth due to investment gains [2] Financial Highlights - A milestone payment of **US$300 million** from Merck to LaNova has been received, which will be recorded in 2H25 after sharing **25%** with Genscript and tax deductions [2] - The company has a cost advantage of **20%-50%** lower than peers due to scale effects of large pharma [2] Regulatory and Market Considerations - For biosimilar VBP, management expressed low expectations for nationwide execution due to potential supply issues and a shift in policymakers' focus towards drug quality [2] - Smooth progress was noted in NRDL renewal negotiations for anlotinib, KRAS G12C, and PD-1 [2] Business Development Goals - The company aims to close a major licensing deal with upfront payments exceeding **US$100 million** by the end of 2025, emphasizing improved experience in business development negotiations [3] - Promising assets in the pipeline include: - **LM-108**: Potential first-in-class CCR8 mAb - **AP025 (FGF21)**: Global rights obtained from Ampsource Bio, potentially better efficacy for MASH, could be developed with GLP-1 - **PD-1/IL2**: Targeting IND in 2026 with a potentially better safety profile - **EGFR/cMET bispecific antibody**: Phase 1 clinical data readout expected in 2026 - **PD-1/CTLA-4 bispecific**: Broader therapeutic window anticipated [3] Price Target and Risks - The 12-month SOTP-based price target is **HK$6.19**, with a current price of **HK$7.12**, indicating a downside of **13.1%** [7][8] - Key downside risks include: - Broader price cuts on the generics portfolio - Delays in regulatory approvals for key products - Low returns on R&D investments due to resource allocation issues - Below-expectation ramp-up of innovative drugs [7] Market Capitalization and Financial Metrics - Market capitalization stands at **HK$134.4 billion** (approximately **US$17.3 billion**) [8] - Revenue projections for the next few years are as follows: - **2024**: **28,866.2 million RMB** - **2025E**: **33,640.4 million RMB** - **2026E**: **35,858.2 million RMB** - **2027E**: **38,682.4 million RMB** [8] Analyst Ratings - The company is rated as a "Buy" by Goldman Sachs, with a focus on its innovative pipeline and growth potential [8] Additional Considerations - The report includes disclosures regarding potential conflicts of interest due to Goldman Sachs' business relationships with the company [4][17] - Analysts emphasize the importance of considering this report as one of several factors in investment decisions [4]

Financial Data and Key Metrics Changes - Total revenues for Q2 2025 were $3,580 million, down approximately 2% year-over-year, but operational revenue growth was approximately 3% when excluding the impact from Indoor [27][28] - Adjusted gross margin for the quarter was 56.6%, consistent with expectations, and operating expenses decreased due to planned cost-saving initiatives [31][32] - Free cash flow generated in the quarter was $167 million, with an adjusted figure of $241 million when excluding transaction-related costs [32] Business Line Data and Key Metrics Changes - In developed markets, brand performance helped offset the Indoor impact, with European business growing approximately 2% and brands portfolio growing approximately 3% [28] - North American business decreased 11% year-over-year, primarily due to Indoor impact and competition, while Emerging Markets saw a 1% increase driven by Turkey and Emerging Asia [29] - Greater China net sales grew 9%, benefiting from proactive patient choice and customer purchasing patterns [30] Market Data and Key Metrics Changes - The company serves approximately one billion patients worldwide each year, with a global supply chain supporting patient access [13] - The U.S. market is expected to see continued growth in generics, although moving additional manufacturing of non-complex generics to the U.S. is deemed difficult in the short term [14][15] - The company anticipates no material impact from proposed U.S. tariffs on its 2025 financial picture, while monitoring developments closely [12][35] Company Strategy and Development Direction - The company is focused on driving strong commercial execution, advancing its late-stage pipeline, and exploring strategic business development opportunities [6][11] - The enterprise-wide strategic review aims to position the company for sustainable growth in 2026 and beyond, with updates expected in the Q3 earnings call [11][54] - The company is committed to returning capital to shareholders through dividends and share buybacks, having returned over $630 million year-to-date [10][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, citing a strong business foundation and a maturing late-stage pipeline [15][16] - The company reiterated its 2025 financial guidance, expecting to be in the top half of the range for revenue and adjusted EPS [15][34] - Management acknowledged the challenges posed by tariffs but does not anticipate a material financial impact in 2025 [48][35] Other Important Information - Five of the six anticipated Phase III readouts have shown positive results, reinforcing the strength of the company's pipeline [7][18] - The company is making progress on remediation efforts at its Indoor facility, with plans to discuss reinspection with the FDA [11][69] - The company has received FDA approval for dorunavir tablets manufactured at its Nashik facility, indicating positive operational progress [12][70] Q&A Session Summary Question: Capital allocation priorities and growth expectations - Management emphasized a balanced approach to capital allocation, focusing on returning capital to shareholders while building a growth portfolio through strategic business development [40][41] Question: Impact of tariffs on revenue from India versus EU - Management stated that it is monitoring the situation closely and does not anticipate a material financial impact from tariffs in 2025 [48] Question: Performance of the China business - The China business saw a 9% operational growth, with expectations for moderate growth in the future, driven by strong brand equity and proactive patient demand [55][56] Question: Contribution from new products in developed markets - Management expects to generate approximately $450 million to $550 million from new product revenue, with a back-half weighting based on approval and launch timing [61][62] Question: Commercial strategy for meloxicam - The company is in the midst of launch planning for meloxicam, focusing on market research and positioning, with expectations for significant opportunity in the acute pain market [66][67]